Search company, investor...

Bold Therapeutics

bold-therapeutics.com

Founded Year

2018

Stage

Grant - II | Alive

Total Raised

$6.28M

Last Raised

$800K | 1 yr ago

About Bold Therapeutics

Bold Therapeutics is a clinical stage biotechnology company developing first-in-class cancer therapy for the treatment of gastric, pancreatic, colorectal, and other cancers in combination with existing anti-cancer therapies.

Headquarters Location

850 West Hastings St Suite 515

Vancouver, British Columbia, V6C1E1,

Canada

604-262-9899

Missing: Bold Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bold Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bold Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bold Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Bold Therapeutics Patents

Bold Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Cannabinoids
  • Chemical synthesis
  • Designer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/4/2020

6/22/2021

Cannabinoids, Designer drugs, Indazoles, Indazolecarboxamides, Chemical synthesis

Grant

Application Date

2/4/2020

Grant Date

6/22/2021

Title

Related Topics

Cannabinoids, Designer drugs, Indazoles, Indazolecarboxamides, Chemical synthesis

Status

Grant

Latest Bold Therapeutics News

Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences

Oct 14, 2022

News provided by Share this article Share this article VANCOUVER, BC, Oct. 14, 2022 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they are attending the BIO-Europe 2022 conference in Leipzig, Germany from October 24 – 26, as well as presenting at the BIO-Europe Virtual Conference from November 2 - 4. Bold Therapeutics Inc. Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest. Collectively, these effects result in cell death in both sensitive and resistant cancers, giving BOLD-100 the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies ranging from traditional chemotherapies to targeted therapies to immuno-oncology agents. BOLD-100 is currently being studied in a multinational Phase 2 trial in the treatment of advanced gastrointestinal (bile duct, colorectal, gastric and pancreatic) cancers actively enrolling at 13 clinical sites: six in Canada; two in the U.S.; and five in South Korea. Bold Therapeutics presented initial data from this Phase 2 trial at the 2022 American Society of Cancer Oncology (ASCO) Annual Meeting in June 2022. In addition to demonstrating that BOLD-100 was safe and generally well-tolerated, this data showed remarkable outcomes in the treatment of 3rd line or later treatment-resistant metastatic colorectal cancer (mCRC) in combination with FOLFOX – including in patients that had previously failed on FOLFOX alone. Subsequent data has both expanded and strengthened these advantages. Consequently, Bold Therapeutics expects to receive a Breakthrough Therapy Designation in the treatment of 3rd line or later treatment-resistant metastatic colorectal cancer (mCRC) and potentially other gastrointestinal cancer indications as well. Bold Therapeutics expects to present this robust data set at a major cancer conference in early 2023. In the interim, Bold Therapeutics is meeting with interested investors as well as potential development and commercialization partners and is willing to share the full clinical data set under confidentiality. For more information, please visit the Company's website at www.bold-therapeutics.com  or the BIO-Europe conference website https://informaconnect.com/bioeurope/ Contact: E. Russell McAllister, CEO (604) 262-9899

Bold Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bold Therapeutics Rank

Bold Therapeutics Frequently Asked Questions (FAQ)

  • When was Bold Therapeutics founded?

    Bold Therapeutics was founded in 2018.

  • Where is Bold Therapeutics's headquarters?

    Bold Therapeutics's headquarters is located at 850 West Hastings St, Vancouver.

  • What is Bold Therapeutics's latest funding round?

    Bold Therapeutics's latest funding round is Grant - II.

  • How much did Bold Therapeutics raise?

    Bold Therapeutics raised a total of $6.28M.

  • Who are the investors of Bold Therapeutics?

    Investors of Bold Therapeutics include National Research Council Canada.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.